LAURUSLABS share price target 2026

BazaarBaazi does not publish a SEBI-registered price target on LAURUSLABS. The desk reads structural support and resistance inside each show against the printed spot; the most recent editorial line is Systematic Read on 21 Jul 2026.

The BazaarBaazi Crack Score for LAURUSLABS is 98 out of 100 as of 21 Jul 2026, a high conviction reading. It is a computed conviction number from the signed stance, how consistent the recent verdicts have been, the quality of the printed structure, and how fresh the review is. It is a transparency signal, not investment advice.

Strike-level option inventory for LAURUSLABS is unavailable, so BazaarBaazi withholds participant, direction and positioning claims. The editorial chart stance is not substituted for an option-chain observation.

LAURUSLABS sits in Healthcare (mid cap), indicative market cap ~86,930 cr (indicative), ISIN INE947Q01028. The peers BazaarBaazi reads alongside it are GLAND PHARMA LIMITED, Eris Lifesciences Limited, ACUTAAS CHEMICALS LIMITED. A systematic, data-only read on LAURUS LABS LIMITED: where it trades versus its 50-day and 200-day lines, the live 52-week range, and momentum, refreshed from the scanner's real price series each run.

This page is one evergreen URL refreshed in place. The Crack Score and levels re-compute on every BazaarBaazi end-of-day run, and the dated stamp shows the last refresh. The latest signed verdict on LAURUSLABS is bullish, published in Systematic Read on 21 Jul 2026.

On the 2026-07-21 run of the 500-name BazaarBaazi setup scanner, LAURUS LABS LIMITED sits in the Scanned tier with a setup score of 80/100 (technical 100, fundamental 40). The scanner is a deterministic engine over real OHLCV and official filings, refreshed nightly, and it is a signal rather than investment advice.

BazaarBaazi indexes 30 LAURUSLABS earnings calls going back to 2019-05-31, latest 2026-05-31. Every entry on this page links straight to the transcript PDF the company filed with the exchange, so you read management in the primary source.

LAURUS LABS LIMITED reported a net profit of Rs 282 cr for Q4 FY26 (the quarter ended 31 March 2026). The figure is from the company's official NSE filing.

LAURUS LABS LIMITED reported revenue of Rs 1,812 cr for Q4 FY26. The figure is from the company's official NSE filing.

BazaarBaazi gives LAURUS LABS LIMITED's Q4 FY26 result a Result Pulse of 64 out of 100, with a verdict of Steady. The Result Pulse is a BazaarBaazi editorial score for the quality of the filed result, not investment advice.

Laurus Labs Ltd's two most material recent disclosures are a regulatory dated 14 Jul 2026, "Certificate under SEBI (Depositories and Participants)…", and an investor meet dated 09 Jul 2026, "Schedule of meet". Both link to the company's own official filing on the BazaarBaazi stock page.

Yes. Laurus Labs Ltd filed a dividend disclosure on 08 May 2026, filed as "Interim Dividend - Rs 1.20 Per Share". Any amount shown is the exchange's own record, linked from the BazaarBaazi stock page. A dividend is a declared payout, not a forecast of future returns.

Laurus Labs Ltd's most recent board-meeting disclosure on record dated 08 Jun 2026 reads "Notice of Annual General Meeting to be held on July 02, 2026". That is the agenda as filed with the exchange, linked from the BazaarBaazi stock page, and BazaarBaazi adds no claim of its own to it.

Laurus Labs Ltd filed a credit-rating disclosure on 03 Jul 2026, recorded with the exchange as "Credit Rating". The detail sits in the linked filing on the BazaarBaazi stock page. A rating action is an agency view on debt, separate from the share price.